NEXT Financial Group Inc cut its position in Astrazeneca PLC (NYSE:AZN) by 49.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,274 shares of the company’s stock after selling 3,189 shares during the period. NEXT Financial Group Inc’s holdings in Astrazeneca PLC were worth $113,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in shares of Astrazeneca PLC in the 2nd quarter valued at about $105,000. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Astrazeneca PLC by 18.4% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after buying an additional 846 shares during the period. Finally, Westport Asset Management Inc. acquired a new stake in shares of Astrazeneca PLC in the 2nd quarter valued at about $170,000. Institutional investors own 14.44% of the company’s stock.

Astrazeneca PLC (AZN) traded up $0.35 during trading on Wednesday, hitting $33.73. 1,358,400 shares of the company’s stock traded hands, compared to its average volume of 4,777,554. Astrazeneca PLC has a 1 year low of $25.55 and a 1 year high of $35.60. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The company has a market cap of $84,514.69, a PE ratio of 7.97, a P/E/G ratio of 3.15 and a beta of 0.75.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business posted $1.32 EPS. Astrazeneca PLC’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts expect that Astrazeneca PLC will post 1.93 EPS for the current fiscal year.

Several brokerages have recently commented on AZN. Citigroup Inc. upgraded Astrazeneca PLC to a “buy” rating in a research note on Wednesday, October 18th. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BMO Capital Markets set a $38.00 target price on Astrazeneca PLC and gave the company a “buy” rating in a research note on Tuesday, October 31st. Cowen and Company restated a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a research note on Friday, July 28th. Finally, Morgan Stanley downgraded Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $34.20.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/next-financial-group-inc-trims-stake-in-astrazeneca-plc-azn/1719787.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.